Valuation : BioNTech SE

Market Cap 22.1B 25.64B 20.72B 18.91B 35.63B 2,451B 35.74B 246B 95.9B 1,237B 96.27B 94.18B 4,102B P/E 2026 *
-15.6x
P/E 2027 * -17x
Enterprise Value 10.73B 12.45B 10.06B 9.18B 17.3B 1,190B 17.35B 119B 46.56B 601B 46.74B 45.72B 1,991B EV / Sales 2026 *
5.94x
EV / Sales 2027 * 6.65x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-8.37%
1 week-12.43%
Current month+12.69%
1 month+10.41%
3 months+9.24%
6 months-7.40%
Current year+7.22%
1 week 98.8
Extreme 98.8
116.87
1 month 88.2
Extreme 88.2
120.33
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
374.85
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/5/26 Free

Chief Operating Officer

22,655 0.0094%
12/5/26 Free

Chief Financial Officer

33,982 0.0141%
12/5/26 Free

Head of Human Resources

18,879 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
-8.37%-12.43%+0.14%-15.42% 25.64B
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
-1.83%+3.29%+22.09%+195.17% 12.33B
Average -2.00%-1.40%+55.58%+192.68% 29.43B
Weighted average by Cap. -1.93%-1.30%+55.68%+154.60%

Financials

2026 *2027 *
Net sales 1.81B 2.1B 1.69B 1.55B 2.91B 200B 2.92B 20.1B 7.84B 101B 7.87B 7.7B 335B 1.81B 2.1B 1.7B 1.55B 2.92B 201B 2.93B 20.17B 7.87B 102B 7.9B 7.73B 337B
Net income -1.38B -1.6B -1.29B -1.18B -2.22B -153B -2.23B -15.33B -5.98B -77.14B -6B -5.87B -256B -1.31B -1.52B -1.23B -1.12B -2.11B -145B -2.12B -14.56B -5.68B -73.27B -5.7B -5.58B -243B
Net Debt -11.37B -13.19B -10.66B -9.73B -18.33B -1,261B -18.39B -126B -49.34B -637B -49.53B -48.46B -2,111B -10.03B -11.64B -9.4B -8.59B -16.17B -1,113B -16.22B -112B -43.54B -562B -43.71B -42.75B -1,862B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
28/08/26 US$102.08 -8.37% 3,072,881
27/08/26 US$111.40 -1.03% 1,552,570
26/08/26 US$112.56 -1.31% 1,255,277
25/08/26 US$114.05 +1.09% 1,359,359
24/08/26 US$112.82 -3.22% 1,851,011
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
87.96EUR
Average target price
103.67EUR
Spread / Average Target
+17.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock